The cost gap between providers in 2025 makes a real difference to your wallet
These medications are available by prescription only
The cardiovascular outcome studies under way for incretin-based medications (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation [LEADER] with liraglutide [clinicaltrials.gov, NCT01179048] [27], Exenatide Study of Cardiovascular Event Lowering [EXCSEL] with exenatide once weekly [NCT01144338], Trial Evaluating Cardiovascular Outcomes with Sitagliptin [TECOS] with sitagliptin [NCT00790205], Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus [SAVOR-TIMI 53] with saxagliptin [NCT01107886] [28], and Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) with linagliptin [NCT01243424]) will help in that respect, although the number of events from a single trial will probably be too low for definite answers
Many patients are busy professionals or active adults who simply need better energy, focus, sleep, and recovery to keep up with their lives
In its latest update, the FDA emphasized that the compounded versions of GLP-1 receptor agonists should only be used when the FDA-approved, commercially available options are not available or if a patient has a legitimate medical need for a compounded version, such as an allergy to an ingredient in the commercially available product
